0001127602-23-014612.txt : 20230504
0001127602-23-014612.hdr.sgml : 20230504
20230504203224
ACCESSION NUMBER: 0001127602-23-014612
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230502
FILED AS OF DATE: 20230504
DATE AS OF CHANGE: 20230504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REESE DAVID M
CENTRAL INDEX KEY: 0001748434
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 23890768
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
4
1
form4.xml
PRIMARY DOCUMENT
X0407
4
2023-05-02
0000318154
AMGEN INC
AMGN
0001748434
REESE DAVID M
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
1
EVP, Research and Development
0
Common Stock
2023-05-02
4
A
0
3814
0
A
55527
D
Common Stock
2023-05-03
4
F
0
819
235.97
D
54708
D
Nqso (Right to Buy)
235.97
2023-05-02
4
A
0
32250
0
A
2025-05-02
2033-05-02
Common Stock
32250
32250
D
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.
These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.
/s/ David M. Reese
2023-05-03